VYNE: the cash flow

MyFinsight

For the year ending 2025-12-31, VYNE had $4,101K increase in cash & cash equivalents over the period. -$33,124K in free cash flow.

Cash Flow	2025-12-31
Royalty revenues-Royalty	570
Research and development-Repibresib VYN201	8,487
Research and development-Research And Development Of VYN202	7,756
Other segment items	2,994
General and administrative	11,082
Total operating expenses	30,319
Operating loss	-29,749
Other income, net	3,017
Loss from continuing operations before income taxes	-26,732
Income tax expense	4
Loss from continuing operations	-26,736
Income (loss) from discontinued operations, net of income taxes	253
Net loss	-26,483
Depreciation	23
Share-based compensation	2,308
Amortization of premium or discount on marketable securities	-778
Unrealized loss on cash equivalents	0
Trade receivables, prepaid expenses and other assets and operating lease right of use assets	-4,214
Trade payables, accrued expenses, employee related obligations and other long-term liabilities	-12,309
Operating lease liabilities	-99
Net cash used in operating activities	-33,124
Purchase of property and equipment	0
Proceeds from the sale and maturity of marketable securities	68,300
Purchases of marketable securities	30,932
Net cash provided by investing activities	37,368
Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net	-143
Net cash used in financing activities	-143
Increase (decrease) in cash and cash equivalents	4,101
Cash and cash equivalents at beginning of the year	19,926
Cash and cash equivalents at end of the year	24,027

Unit: Thousand (K) dollars (except for numbers of shares and EPS).